Avalyn to Present New Long-Term Data on Key Pulmonary Fibrosis Drug AP01
AVLN is trading near its 52-week low of $25.05 (11% above the low) on light trading volume (0.2× avg).
Summary
Avalyn Pharma announced it will present additional long-term data for AP01, its inhaled pirfenidone for pulmonary fibrosis, at the European Alliance of Associations for Rheumatology 2026 conference. This news follows the company's recent IPO in late April. AP01 is a critical pipeline asset, and the full data presentation will be closely watched for insights into its efficacy and safety profile.
At the time of this announcement, AVLN was trading at $27.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $25.05 to $32.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.